Processa Pharmaceuticals, Inc. — Director's Dealing 2021

Apr 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-04-06

Reporting Person: BESSER JAMES E (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-06	Common Stock, $0.01 par value	S	31771	$10.91	Disposed	1064300	Direct
2021-04-07	Common Stock, $0.01 par value	S	16000	$10.67	Disposed	1048300	Direct
2021-04-08	Common Stock, $0.01 par value	S	400000	$10.76	Disposed	648300	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.01 par value	405000	Indirect

Footnotes

F1: These securities are directly owned by Manchester Explorer, L.P. and JEB Partners, L.P. These securities are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P.; these securities may also be deemed to be indirectly beneficially owned by James E. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC.

F2: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.